À compter du 1er décembre 2023, l’accès à POEMs et à Essential Evidence Plus ne fera plus partie des avantages offerts aux membres de l’AMC.
Question clinique
Should primary care clinicians offer risk-reducing medications, such as tamoxifen, raloxifene, or aromatase inhibitors, to women at increased risk for breast cancer?
L’Essentiel
In this updated 2019 review, The U.S. Preventive Services Task Force (USPSTF) recommends that primary care clinicians offer risk reducing medications, such as tamoxifen, raloxifene, or aromatase inhibitors, to women at increased risk for breast cancer and at low risk for adverse medication effects. (B recommendation) This recommendation applies only to asymptomatic women 35 years and older, including women with previous benign breast lesions. The Task Force recommends against routine use of risk-reducing medications in women not at increased risk for breast cancer. (D recommendation) These recommendations are consistent with the 2013 USPSTF recommendation statement. 2c
Référence
Plan de l'etude: Practice guideline
Financement: Government
Cadre: Population-based
Sommaire
In this updated review, the Task Force found good evidence that risk-reducing medications, including tamoxifen, raloxifene, or aromatase inhibitors do reduce the risk of invasive estrogen receptor-positive breast cancer in post menopausal women. Tamoxifen and raloxifene increase the risk of venous thromboembolic events, and tamoxifen increases the risk of endometrial cancer and cataracts. Aromatase inhibitors may increase the risk of stroke and fractures. Thus, women with a 3% or higher risk for breast cancer in the next 5 years are most likely to receive more benefit than harm from treatment and should be offered these medications if their risk of harm is low. The Task Force found that current risk assessment tools perform only modestly in predicting an individual woman's risk of breast cancer and do not recommend any particular tool. The American Academy of Family Physicians supports the 2013 USPSTF recommendation.
Reviewer
David C. Slawson, MD
Professor and Vice Chair of Family Medicine for Education and Scholarship
Atrium Health
Professor of Family Medicine, UNC Chapel Hill
Charlotte, NC
Commentaires
Sub: B and D recommended by doctors to breast cancer patients.
Dear respected Team-CMA-Canada,
I have already read the above subject/tropic on breast cancer related patients.
Patients/clients are advised and prescribed by doctors /breast cancer protection specialist/family doctors the medicine B and D . These are very helpful for patients at high risks breast cancer to prevent.
Now there are many type of treatment methods/policy to protect human /women breast cancer which are given here:
(01) Only medicine.
(02)Laser surgery /Laser Treatment.
(03)Hit /Steam Hit Therapy.
(04) Natural recognized medicine by very experienced/trained doctors
(05) Homeopathy Recognized medicine by highly trained/experienced recognized board doctors.
My best wishes to global patients/global doctors for good health and peaceful life atmosphere.
Respectfully.
Dr.Muhammad Arif Rana
Global Family Doctor (LDM-224)-WONCA at SIG Based in Manikganj-Bangladesh.
International Resident Doctor (IMG)-CMAID-680777-CMA-Canada.
Health Professional Member ID-52698-MDS-USA.
Associate Member-FDA-UK.
Registered User -AAFP-USA.
Registered User-MGH-Psychaitry Academy -MA-USA.
(SIG).
Email:muhammadarifrana3@gmail.com
Manikganj-Bangladesh.
Date : November 15-2019-Friday-07:46 PM.
(Best wishes and Respectfully)